Excision BioTherapeutics is a biopharmaceutical company based in San Francisco focused on developing gene therapies against HIV infection.
The company has a single, CRISPR–Cas9 based therapy, EBT-101, under investigation. Initial investigation into the therapy was conducted by the lab of Kamel Khalili, a professor at Temple University.[1][2][3][4] In July 2023 the US Food and Drug Administration granted EBT-101 fast-track status.[5] In October 2023 an early-stage study on 3 people reported that the treatment appeared to be safe with no major side effects.[6] In March 2024 it was revealed that EBT-101 did not maintain HIV viral suppression when used alone at the initial dose tested, although it might have delayed viral rebound in one trial participant.